Crinetics Pharmaceuticals to Share Second Quarter Insights
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a progressive clinical stage pharmaceutical entity, is gearing up to announce its financial results for the second quarter of 2025. The highly anticipated event is slated for August 7, 2025, after the market’s closure. Management is preparing to engage with stakeholders through a conference call scheduled to take place at 4:30 p.m. ET.
Conference Call Details
For those wishing to participate in this financial update, there are dedicated call-in options:
- Domestic Calls: 1 833-470-1428
- International Calls: 1 404-975-4839
- Access Code: 899803
Listeners can also attend via a live webcast, accessible through the Crinetics Pharmaceuticals website or directly via a provided link.
Webcast Instructions
To ensure seamless participation, attendees are encouraged to connect at least 15 minutes ahead of the official start time. The live webcast will also be kept on record, allowing investors and interested parties to access archived content later via the Investor Relations section on Crinetics' official website.
Overview of Crinetics Pharmaceuticals
Crinetics Pharmaceuticals stands at the forefront of medical innovation focusing on endocrine diseases and related disorders. The company’s lead candidate, PALSONIFY (paltusotine), is significant as it represents the first oral, once-daily, selective somatostatin receptor type 2 (SST2) nonpeptide agonist. This innovative therapy is currently undergoing clinical development for conditions like acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
Pipeline and Development
In addition to PALSONIFY, Crinetics is advancing Atumelnant, targeting conditions such as congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The company takes pride in its drug candidates being novel, orally delivered, small molecules, each developed through rigorous in-house research. Their exploration into various endocrine disorders showcases their commitment to healthcare advancements.
The company’s research isn't limited to already identified conditions. The development team is also actively focusing on several programs addressing hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), obesity, diabetes, and GPCR-targeted oncology indications. This broad approach reflects Crinetics' mission to meet unmet medical needs and provide transformative treatment options.
Contact Information for Investor Relations and Media
For those wishing to communicate about investment opportunities, Gayathri Diwakar, Head of Investor Relations at Crinetics, is available at gdiwakar@crinetics.com or by phone at (858) 345-6340. Inquiries related to corporate communications can be directed to Natalie Badillo, Head of Corporate Communications, at nbadillo@crinetics.com or (858) 345-6075.
Frequently Asked Questions
What is the purpose of Crinetics Pharmaceuticals' conference call?
The conference call aims to discuss the company’s financial results for Q2 2025 along with a business update.
When will Crinetics Pharmaceuticals report its second quarter results?
The results will be reported on August 7, 2025, after the market closes.
Who can join the conference call?
Any interested parties, including investors and analysts, can join by using the provided call-in numbers or via the webcast.
What is PALSONIFY?
PALSONIFY is Crinetics' lead drug candidate, designed to address acromegaly and carcinoid syndrome through a novel oral delivery method.
How can I access the archived webcast?
The archived webcast will be available in the Investor Relations section of the Crinetics Pharmaceuticals website following the live event.
